 Primary objective: Comparison of independently assessed progression free survival PFS in subjects administered Bevacizumab Temsirolimus vs. those administered Bevacizumab Interferon-Alfa. Secondary objectives: safety, Investigator assessed PFS, objective response rate independently assessed, and overall survival. 